Rapid response of nail psoriasis to secukinumab in patients with moderate to severe psoriasis after 12 weeks of treatment with a total of 24 weeks of follow-up.

Gang Min Go Yong Jun HongHyun Ji LeeMiri Kim

Published in: The Australasian journal of dermatology (2024)

Secukinumab rapidly improved nail psoriasis after 12 weeks of treatment, with further enhancement at 24 weeks, suggesting its potential as a potent therapeutic option for nail psoriasis.

Keyphrases

gestational age
atopic dermatitis
early onset
high intensity
rheumatoid arthritis
systemic lupus erythematosus
preterm birth
anti inflammatory
smoking cessation
hidradenitis suppurativa